register

News & Trends - Pharmaceuticals

Lilly’s $960M deal in immunological and neurodegenerative diseases

Health Industry Hub | February 22, 2021 |
[Total: 1    Average: 5/5]

Pharma News: Eli Lilly and Rigel Pharmaceuticals announced a global exclusive license agreement and strategic collaboration to co-develop and commercialise a receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitor, for all indications including autoimmune and inflammatory diseases.

Pursuant to the collaboration, Lilly will also lead all clinical development of brain penetrating RIPK1 inhibitors in central nervous system (CNS) diseases.

Rigel’s lead RIPK1 inhibitor, R552, will begin Phase 2 clinical trials in 2021 as part of the collaboration. Rigel also has ongoing pre-clinical activities with its lead CNS penetrant RIPK1 inhibitor candidates.

“At Lilly, our immunology strategy is focused on the pursuit of novel targets that have the potential to develop into best-in-class medicines for patients with autoimmune conditions,” said Ajay Nirula, M.D., Ph.D., vice president of immunology at Lilly. “RIPK1 inhibitors are a promising approach, and R552 is an exciting addition to our immunology pipeline. We look forward to working with Rigel to advance its clinical development.”

“We are very excited to form this strategic partnership with Lilly. This collaboration will provide significant resources and expertise to support a broad investigation in multiple disease indications with our RIPK1 inhibitors,” said Raul Rodriguez, Rigel’s president and CEO. “With Lilly’s extensive knowledge in immune and CNS diseases, they are our ideal partner to ensure the clinical and commercial success of our RIPK1 inhibitor program.”

Under the terms of the agreement, Lilly will pay an upfront cash payment to Rigel of $125 million. Rigel may also be eligible to receive up to $835 million in potential development, regulatory, and commercial milestone payments.

Last year, Sanofi and Denali dropped their lead RIPK1 candidate SAR 443060 on toxicity issues that forced them to go back and focus on a follow-up compound.

In 2019, GlaxoSmithKline abandoned a RIPK1 drug it had been hoping to pair with checkpoint inhibitors in oncology, GSK3145095, after it failed a pancreatic cancer study.

GSK’s other clinical-stage RIPK1 inhibitor GSK2982772, aimed at inflammatory diseases, is listed as being in phase 1 for psoriasis in the company’s latest pipeline update.

Another organisation with an RIPK1 inhibitor nearing clinical development is Australia’s GenFleet Therapeutics, which is due to start phase 1 trials of its GFH312 candidate in March 2021.


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Medical Technology

MedTech News - Johnson & Johnson breaking down barriers to gender equality

Johnson & Johnson breaking down barriers to gender equality

Health Industry Hub | February 26, 2021 |

MedTech News: The Johnson & Johnson Family of Companies in Australia is pleased to announce that the company has been […]

More


Human Resources

Human Resource Management - National gender pay gap drops to 13.4%

National gender pay gap drops to 13.4%

Health Industry Hub | February 26, 2021 |

Human Resources: The Workplace Gender Equality Agency announced today that that national gender pay gap has dropped to 13.4%, a decline […]

More


News & Trends - Medical Technology

MedTech News - Philips one of first MedTechs to become carbon neutral

Philips, one of first MedTechs to become carbon neutral

Health Industry Hub | February 26, 2021 |

MedTech News: Philips Healthcare Australia, a global leader in health technology, has successfully met all the targets set out in […]

More


Social Responsibility

Social Responsibility and Community Engagement - The race to win the 2021 Medicines Australia, Kosi Pharma-Cup

The race to win the 2021 Medicines Australia Kosi Pharma-Cup

Health Industry Hub | February 26, 2021 |

The countdown is on for Rare Cancer Australia’s Kosi Challenge and the battle to win the Pharma-Cup sponsored by Medicines […]

More